Literature DB >> 35125722

Serial Evaluation of T cell Subsets in Paediatric Acute Myeloid Leukaemia- a Prospective Study.

Anuj Kumar Bansal1,2,3, Surender Kumar Sharawat1,2,3, Ritu Gupta4,2, Sreenivas Vishnubhatla5,3, Sameer Bakhshi1,2,3.   

Abstract

PURPOSE: There is paucity of data regarding T-cells in paediatric AML patients. The aim of this prospective study was to evaluate trend of T-cell subset during disease course of paediatric AML patients and to see its correlation with patient characteristics and survival outcome.
METHODS: T-cell subsets (CD3, CD4 and CD8) were evaluated by flow-cytometry at diagnosis, post-induction, post-treatment completion, at 3 months and 6 months post-treatment completion, and relapse in 29 pediatric AML patients. Trend of T-cells was plotted between group A (those in continuous remission) and group B (those who relapsed) patients.
RESULTS: Patients with high WBC count had significantly higher number of CD3, CD4 and CD8 cell. Baseline Tcell subsets did not affect CR, EFS and OS; however, higher than median CD4 count predicted improved DFS [58% vs 25%; HR = 0.306 (0.10-0.93); P = 0.037]. On serial follow-up from post-induction till 3 months after completion of therapy, there was no difference in the absolute values of T cell subsets between group A and B patients.
CONCLUSION: Our study demonstrated T cell subsets are increased in AML subjects with high WBC count. CD4 cells have a positive impact on DFS. Serial follow-up has no impact on T cell subsets. Further studies in larger patient cohorts are needed to evaluate if CD4 population may serve as an immune biomarker for AML. © Indian Society of Hematology and Blood Transfusion 2021.

Entities:  

Keywords:  CD3; CD4; CD8 cells; Paediatric acute myeloid leukaemia

Year:  2021        PMID: 35125722      PMCID: PMC8804101          DOI: 10.1007/s12288-021-01436-7

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  6 in total

Review 1.  Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies.

Authors:  David L Porter
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  Paediatric reference values for the peripheral T cell compartment.

Authors:  E J H Schatorjé; E F A Gemen; G J A Driessen; J Leuvenink; R W N M van Hout; E de Vries
Journal:  Scand J Immunol       Date:  2012-04       Impact factor: 3.487

Review 3.  Regulatory T cells, tumour immunity and immunotherapy.

Authors:  Weiping Zou
Journal:  Nat Rev Immunol       Date:  2006-04       Impact factor: 53.106

4.  Quantification and cytokine production of circulating lymphoid and myeloid cells in acute myelogenous leukaemia.

Authors:  N Panoskaltsis; C D L Reid; S C Knight
Journal:  Leukemia       Date:  2003-04       Impact factor: 11.528

5.  Bone marrow T-cell percentage: A novel prognostic indicator in acute myeloid leukemia.

Authors:  Manar M Ismail; Nahla A B Abdulateef
Journal:  Int J Hematol       Date:  2016-12-01       Impact factor: 2.490

6.  Profiles of activation, differentiation-markers, or β-integrins on T cells contribute to predict T cells' antileukemic responses after stimulation with leukemia-derived dendritic cells.

Authors:  Valentin Vogt; Julia Schick; Christian Ansprenger; Marion Braeu; Tanja Kroell; Doris Kraemer; Claus-Henning Köhne; Andreas Hausmann; Raymund Buhmann; Johanna Tischer; Helga Schmetzer
Journal:  J Immunother       Date:  2014 Jul-Aug       Impact factor: 4.456

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.